Mapp Biopharmaceutical
Mapp Biopharmaceutical: Innovating infectious disease prevention with ZMapp Ebola vaccine.
Founded
2003Mapp Biopharmaceutical: Innovating infectious disease prevention with ZMapp Ebola vaccine.
Mapp Biopharmaceutical, founded in 2003 by Larry Zeitlin and Kevin Whaley, is headquartered in San Diego, California. The company’s core mission is to develop novel pharmaceuticals aimed at preventing and treating infectious diseases, with a particular focus on unmet global health and biodefense needs. Mapp Biopharmaceutical is best known for developing ZMapp, an experimental drug designed to combat the Ebola virus. The company also works on therapeutics for other infectious diseases, including Marburg virus.
Notable figures affiliated with Mapp Biopharmaceutical include co-founders Larry Zeitlin and Kevin Whaley, who serve as President and CEO, respectively. The company has garnered significant attention for its work on ZMapp, especially during the Ebola outbreaks. Collaborations with organizations such as BARDA have been instrumental in advancing their research and development efforts. Mapp Biopharmaceutical’s impact lies in its innovative approach to addressing critical infectious disease threats, contributing significantly to global health security.
Companies similar to Mapp Biopharmaceutical include Emergent BioSolutions, MBC Pharma, Tempo Therapeutics and Biomarck Pharmaceuticals.
Mapp Biopharmaceutical was founded in 2003.
Mapp Biopharmaceutical's headquarters is located in San Diego, CA, US.
Mapp Biopharmaceutical's most recent funding round was for $16.5M (USD) in June 2019.
As of Jun 23, 2019, Mapp Biopharmaceutical has disclosed funding of $16.5M (USD). Undisclosed round amounts are excluded.
Mapp Biopharmaceutical has 68 employees as of Feb 4, 2024.
Biomarck Pharmaceuticals
